![](/img/cover-not-exists.png)
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
Donovan, Joanne M., Zimmer, Michael, Offman, Elliot, Grant, Toni, Jirousek, MichaelVolume:
57
Language:
english
Journal:
The Journal of Clinical Pharmacology
DOI:
10.1002/jcph.842
Date:
May, 2017
File:
PDF, 464 KB
english, 2017